The kidneys filter large amounts of glucose. To prevent the loss of this valuable fuel, the
tubular system of the kidney, particularly the proximal tubule, has been programmed to …

Heart failure (HF) continues to be a serious public health challenge despite significant
advancements in therapeutics and is often complicated by multiple other comorbidities. Of …

Background Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown
to reduce cardiovascular mortality in heart failure independently of glycemic control and …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment
strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the …

The number of diabetic patients has risen dramatically in recent decades, owing mostly to
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …

The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of effective drugs
managing patients, who suffer from type 2 diabetes (T2D): Landmark clinical trials including …

The liver is not the exclusive site of glucose production in humans in the postabsorptive
state. Robust data support that the kidney is capable of gluconeogenesis and studies have …

Glucose transporters are essential for the heart to sustain its function. Due to its nature as a
high energy-consuming organ, the heart needs to catabolize a huge quantity of metabolic …

Background In pig production, early and abrupt weaning frequently causes weaning stress,
which manifests as oxidative damage, barrier disruption, and digestion and absorption …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce major adverse
cardiovascular events (MACE) in type 2 diabetic (T2DM) patients. Pharmacological …